Navigation Links
Igenica Closes $33 Million in Series C Funding
Date:6/12/2012

BURLINGAME, Calif., June 12, 2012 /PRNewswire/ -- Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.  The financing round was led by new investor Third Rock Ventures, with participation from existing investors The Column Group, Orbimed Advisors and 5AM Ventures.  The closing of the Series C financing increases the total raised by the company to $55 million since the company began operations in January 2009.

Proceeds from the financing will be used to advance the company's monoclonal antibody pipeline toward clinical trials.  These funds will also be used to apply Igenica's unique discovery approach, consisting of the sTAg target discovery platform and the iTAb antibody discovery platform, toward the discovery of new monoclonal antibodies against a broad range of drug targets that have not been previously investigated for the treatment of cancer.

"We are pleased to have Third Rock Ventures, a premier life sciences venture capital firm, lead Igenica's Series C round," said David Goeddel, Ph.D., Executive Chairman of Igenica, Inc.  "Third Rock's investment highlights the broad potential of Igenica's antibody technology and provides strategic flexibility as we execute our operating and business plans.  Moreover, we are now advancing a product candidate toward the clinic that has the potential to improve treatment outcomes for cancer patients."

About Igenica, Inc.
Igenica, Inc. is a biopharmaceutical company pioneering breakthrough antibody-based cancer medicines. The company has integrated innovative technology platforms to address the major challenges to developing effective treatments for multiple oncology indications, with sTAg, a new approach to discovering and prioritizing novel tumor antigens, and iTAb, a functional in vivo antibody screening approach. Collectively, the two technology platforms drive Igenica's drug discovery efforts and promise to identify novel and more effective cancer therapeutics.

Igenica's Board of Directors includes David Goeddel, Ph.D., Managing Partner, The Column Group; John Diekman, Ph.D., Managing Partner, 5AM Ventures; Mark A. Goldsmith, M.D., Ph.D., Venture Partner, Third Rock Ventures; Carl Gordon, Ph.D., CFA, General Partner, Orbimed Advisors; Robert Schreiber, Ph.D., Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology and Tumor Immunology Program Leader for the Siteman Comprehensive Cancer Center at Washington University School of Medicine.

Contact:

John K. Celebi, MBA
Chief Business Officer
Igenica, Inc.
(650) 231-4320


'/>"/>
SOURCE Igenica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. C8 MediSensors Closes $19 million Preferred Stock Financing
2. Boston Scientific Closes Cameron Health Acquisition
3. Stereotaxis Closes $18.5 Million Private Placement Financings
4. Independa Closes Convertible Note Funding at $2.35 Million
5. Novelos Therapeutics Prices $5.4 Million Public Offering
6. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
7. InnoPharma Inc. Raises $8 Million in Venture Debt
8. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
9. Software Pioneer Leaves $10 Million Bequest To Five Leading Non-profits In Health And Drug Policy Reform
10. AssureRx Health Raises $12.5 Million Series C Financing
11. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 Potrero Medical, Inc., ... pleased to announce the appointment of George M. Rapier, ... San Antonio, TX , WellMed is one of ... 200,000 patients and HMO members in Texas ... in 1990 out of his own internal medicine practice, he ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
(Date:2/11/2016)... , Feb. 11, 2016  MiMedx Group, Inc. ... utilizing human amniotic membrane and other birth tissues, human ... to develop and market advanced products and therapies, announced ... Markets, 2016 Global Healthcare Conference in New ... and CEO, Michael J. Senken , Chief Financial ...
Breaking Medicine Technology:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for Plans ... Catholic health care system that’s partnering with Intel on value-based health benefits program ...
(Date:2/11/2016)... Australia (PRWEB) , ... February 11, 2016 , ... ... potential ?" motivational speaker, trainer and author Ray Clarke poses a question as ... personal fulfillment . In his book, "Being in the Being" (published by Partridge ...
(Date:2/11/2016)... City, FL (PRWEB) , ... February 11, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... multi-specialty practice Village Family Practice , will be presenting at the 2016 ... in Las Vegas, Nev. , During his session, “ Coding for Care: ...
(Date:2/11/2016)... ... ... The annual list showcases the 20 Most Promising SharePoint Solution Providers in ... commitment to the SharePoint ecosystem. A panel of experts and members of CIOReview’s editorial ... and promote technology entrepreneurship. , The survey was made at the end of ...
Breaking Medicine News(10 mins):